<DOC>
	<DOCNO>NCT01264211</DOCNO>
	<brief_summary>To evaluate efficacy Diacerein 100 mg daily versus placebo reduce rheumatoid arthritis symptom , add stable oral MTX therapy patient active early RA . To evaluate safety Diacerein 100 mg daily administrate combination oral MTX therapy patient 24 week To investigate potential persistent effect , 4 week Diacerein treatment stop ( carry-over effect )</brief_summary>
	<brief_title>Safety Efficacy Combination Diacerein 100 mg Daily MTX Versus MTX Alone Treatment Early Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Diacetylrhein</mesh_term>
	<criteria>1 . Male female age 18 65 year ; 2 . Active RA ≥ 3 month duration &lt; 2 year , diagnose accord American College Rheumatology ( ACR ) 1987 revise criterion RA ; 3 . RA global functional status class IIII ; 4 . Treatment outpatient basis ; 5 . Treatment MTX minimum 12 week , stable weekly dose ( 1020 mg ) least 4 week randomisation ; 6 . Insufficient response treatment MTX , disease activity score DAS28 &gt; 4.0 time screen randomisation ; DAS28 must change significantly screen baseline visit ( change &lt; 0.6 ) ; 7 . Tender joint count ( TJC ) ≥ 6 ( 68 joint count ) swell joint count ( SJC ) ≥ 6 ( 66 joint count ) screen randomisation ; 8 . Screening ESR ≥ 28 mm/h ; 9 . Evidence adequate contraceptive method woman childbearing potential . Female patient childbearing potential surgically sterile postmenopausal . Adequate contraceptive method hormonal contraceptive , intrauterine device , diaphragm spermicide condom spermicide entire duration study ; 10 . Agreement drink alcohol duration study ; 11 . Ability agreement comply requirement study protocol ; 12 . Having give write informed consent participate study . 1 . History active inflammatory arthritis RA ; 2 . Any uncontrolled medical condition diabetes mellitus , asthma , cardiopulmonary disease , congestive heart failure , neurological disease , etc . ; 3 . Alcohol abuse , define consumption one glass beer wine day ; 4 . Moderate severe liver disease ( cirrhosis , hepatitis , liver insufficiency ) ; 5 . Blood anomaly ( significant cytopenia ) ; 6 . History , currently active primary secondary immunodeficiency ; 7 . Chronic hepatitis B ( HBsAg positive HBcAb positive HBV DNA load ≥ 400 copies/ml ) hepatitis C ( antiHCV positive ) ; 8 . Current know active , history , recurrent bacterial , viral , fungal , mycobacterial infection , infection require hospitalisation treatment i.v . antibiotic within 4 week prior randomisation oral antibiotic within 2 week prior randomisation ; 9 . Treatment biologic DMARDs TNF antagonist , IL 1 receptor antagonist , IL 6 receptor antagonist , CTLA4Ig within 12 week prior randomisation , rituximab within 24 week prior randomisation ; 10 . Treatment nonbiologic DMARDs chloroquine , hydroxychloroquine , penicillamine , sulfasalazine within 4 week prior randomisation , leflunomide , parenteral gold , oral gold within 8 week prior randomisation , azathioprine ciclosporin within 12 week prior randomisation ; 11 . Treatment intraarticular injection depocorticosteroid within 8 week prior randomisation ; 12 . Treatment NSAID oral corticosteroid , unless patient stable dose least 4 week randomisation ( maximal allow daily dose oral corticosteroid equivalent prednisone 10 mg ) ; 13 . Physical therapy alternative therapy , unless patient receive regularly least 4 week randomisation ; 14 . Initiation chronic treatment antihistaminics , antidepressant tranquilisers , within less 12 week randomisation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Efficacy Diacerein</keyword>
	<keyword>Safety Diacerein</keyword>
	<keyword>Carry-over effect Diacerein</keyword>
</DOC>